For healthcare professionals
Mydriasert is indicated to obtain pre-operative mydriasis or for diagnostic purposes where monotherapy is known to be insufficient.1 It is an ophthalmic pellet inserted into the lower conjunctival fornix prior to surgery or diagnostic procedure.1
The lachrymal flow gradually releases the active substances of phenylephrine and tropicamide leading to a wide and stable mydriasis.2
Introduction of Mydriasert can help to improve efficiency in cataract surgery lists.3
Key Features of Mydriasert
Biocompatible, preservative free insert for maximum patient comfort; 96% of patients considered their level of comfort to be good.4
Advantages over mydriatic drops include:
Mydriasert is a hospital only medicine.
The recommended dose is one ophthalmic insert per operated eye to be instilled in the lower fornix a maximum of 2 hours prior to surgery or diagnostic procedure.
DO NOT LEAVE THE OPHTHALMIC INSERT FOR MORE THAN TWO HOURS IN THE LOWER CONJUNCTICAL SAC
Mydriasert is contraindicated in children aged below 12 years. There are no data in children aged 12 to 18 years. Mydriasert is not recommended in these patients.
Do not store above 25°C.
After first opening of the sachet, use immediately. After first use, discard the used insert immediately.
One box of 20 ophthalmic inserts and 20 forceps.
NHS Price: £84 for one box of 20 inserts and 20 forceps
PIP code: 367-6509
Page last updated: 20th January 2025